Sumitomo Pharma Co., Ltd. Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

4506

Classifica tra le azioni #3223
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Prezzo delle azioni
$12.27
Capitalizzazione di mercato
$5.51B
Variazione (1 giorno)
2.20%
Variazione (1 anno)
6.72%
Paese
JP
Scambia Sumitomo Pharma Co., Ltd. (4506)

Categoria

Healthcare
Margine operativo per Sumitomo Pharma Co., Ltd. (4506)
Margine operativo al October 2026 TTM: 10.05%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Sumitomo Pharma Co., Ltd., il margine operativo attuale (TTM) è 10.05%. Alla fine del 2024, il margine operativo era -112.60%.
Storico del margine operativo per Sumitomo Pharma Co., Ltd. da 2005 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
2026 (TTM) 10.05% 39.20%
2025 7.22% -106.41%
2024 -112.60% 712.41%
2023 -13.86% -228.81%
2022 10.76% -22.03%
2021 13.80% -19.95%
2020 17.24% 36.83%
2019 12.60% -33.30%
2018 18.89% 47.35%
2017 12.82% 39.96%
2016 9.16% 46.09%
2015 6.27% -42.32%
2014 10.87% 50.97%
2013 7.20% 23.71%
2012 5.82% -28.68%
2011 8.16% -32.11%
2010 12.02% 1.86%
2009 11.80% -21.75%
2008 15.08% -13.53%
2007 17.44% 48.43%
2006 11.75% 77.49%
2005 6.62% 0.00%
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -97.72%
IN
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.